22 Jul Evotec
Andreas Scheel, Ph.D., Executive Vice President, Head of Cell Therapy
Oct. 6 | 11:00am | FLW Ballroom G
Hamburg, Germany
(NASDAQ:EVT)
Evotec is a biotechnology company driving innovation in drug discovery and development. Combining cutting-edge science, AI-driven innovation, and proprietary technologies such as PanOmics and iPSC, we accelerate the journey from concept to cure. With tailored partnering models, we work with Top 20 Pharma, biotechs, academia, and healthcare stakeholders. Within cell therapy, Evotec offers a fully integrated, end-to-end platform to advance iPSC-based therapies from inception to clinical application. This includes in-house GMP manufacturing capabilities for clinical supply. Evotec’s platform is among the most comprehensive in the industry, encompassing cell types for anti-tumor therapies (NK cells, macrophages, αβ T cells, γδ T cells), regenerative therapies (beta cells, cardiomyocytes, photoreceptors) and immune-modulation therapies. Evotec maintains strategic partnerships with companies such as Sernova and Novo Nordisk. Additionally, Evotec provides integrated drug development solutions, including safety assessment, CMC, process and analytical development, regulatory and clinical services for both autologous and allogeneic cell therapy candidates.
